Joe Todisco, CorMedix CEO
CorMedix hit with second CRL for antifungal treatment, citing manufacturing and API issues
Following a C-suite shuffle, a shuttering of its European operations and a CRL for its treatment to prevent bloodstream infections in patients undergoing chronic …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.